Evicenter
MarkdownMedical informationP&T meetings
VK2735

Chronic weight management

Last updated
184 sources

Section 4 of 6

Clinical evidence

448 evidence topics · 63 sources

Study summaries

VANQUISH-1

Objective
Location and study date
Study design
Extension study after the 78-week treatment period
Eligibility criteria
Treatment
Study outcomes
Rationale for using percent change in body weight as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned participants per arm in the design poster
ArmPlanned participants
Placebo“n=1224”
VK2735 7.5 mg“n=816”
VK2735 12.5 mg“n=1224”
VK2735 17.5 mg“n=1224”
Description of analysis sets
Efficacy and safety analysis sets

No evidence found.

Results
Participant disposition
Baseline characteristics
Demographics and body size compared with NHANES
CharacteristicVANQUISH-1 (N=4660)NHANES
Age, mean (SD), years“50.4 (13.81)”“47.6 (13.97)”
Age 65 years or older“17%”“19%”
Sex, female to male“65%:35%”“51%:49%”
Waist circumference, mean (SD), cm“116.2 (16.13)”“109.2 (11.35)”
BMI, mean (SD), kg/m2“38.3 (7.31)”“33.7 (5.10)”
BMI 27 to less than 30 kg/m2“5%”“33%”
BMI 30 to less than 35 kg/m2“33%”“36%”
BMI 35 to less than 40 kg/m2“28%”“16%”
BMI 40 kg/m2 or higher“33%”“15%”
Age distribution compared with NHANES
Age group, yearsVANQUISH-1NHANES
18 to 34“15%”“28%”
35 to 44“21%”“20%”
45 to 54“24%”“16%”
55 to 64“23%”“17%”
65 to 74“15%”“12%”
Over 75“3%”“7%”
Race and ethnicity compared with NHANES
Race or ethnicityVANQUISH-1NHANES
Non-Hispanic White“56%”“60%”
Hispanic or Latino“21%”“18%”
Non-Hispanic Black“17%”“12%”
Non-Hispanic Asian“2%”“4%”
Other“4%”“6%”
Baseline laboratory values
Measurement, mean (SD)VANQUISH-1 (N=4660)
HbA1c, %“5.5 (0.40)”
Glucose, mg/dL“97.2 (11.18)”
Insulin, µIU/mL“16.4 (15.66)”
Total cholesterol, mg/dL“192.6 (39.69)”
Triglyceride, mg/dL“126.8 (61.85)”
hsCRP, mg/L“6.0 (8.82)”
Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary: limitations evident from the available VANQUISH-1 documents

VANQUISH-1 is ongoing, with primary completion estimated for July 2027 and data expected in the second half of 2027, so no efficacy, patient-reported outcome, or safety result is available. All available information comes from the ClinicalTrials.gov record, company press releases, an investor presentation, company call and conference transcripts, and two congress posters authored by company employees with or without study investigators; no peer-reviewed design or results publication was identified, and the ClinicalTrials.gov record has posted no results.

Reported enrollment differs between documents: the registry lists an estimated 4,500 participants, the enrollment release reported “approximately 4,650 adults”, the baseline poster reported 4,660 participants randomized from 138 sites, and later releases and the investor presentation describe approximately or more than 4,500. The registry lists 137 locations.

The 7.5 mg arm was planned to be smaller than the other arms (816 compared with 1,224 planned participants per arm), so estimates for that dose will be less precise. The trial enrolled participants without diabetes in the United States and Puerto Rico only; 65% of participants were women, and the mean BMI was 38.3 kg/m2, higher than the 33.7 kg/m2 of the NHANES comparison population. Prior use of GLP-1 receptor agonists or dual GLP-1/GIP receptor agonists within 6 months of screening was excluded. The company describes the blinded discontinuation rate only qualitatively. The device changed during the trial, from vial and syringe to an autoinjector introduced in the first quarter of 2026. The extension study, which adds every-other-week and monthly regimens, is expected to report in 2028 and will not inform the primary 78-week analysis.

VANQUISH-2

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using percent change in body weight as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned participants per arm in the design poster
ArmPlanned participants
Placebo“n=306”
VK2735 7.5 mg“n=204”
VK2735 12.5 mg“n=306”
VK2735 17.5 mg“n=306”
Randomized participants per arm in the baseline poster
ArmRandomized participants
Placebo“N=276”
VK2735 7.5 mg“N=185”
VK2735 12.5 mg“N=276”
VK2735 17.5 mg“N=276”
Total“1013 participants were randomized from 127 U.S. study sites”
Description of analysis sets
Efficacy and safety analysis sets

No evidence found.

Results
Participant disposition
Baseline characteristics
Demographics and body size compared with NHANES
CharacteristicVANQUISH-2 (N=1013)NHANES
Age, mean (SD), years“58.3 (11.5)”“59.51 (11.7)”
Age 65 years or older“31%”“38%”
Sex, female to male, %“49:51”“49:51”
Weight, mean (SD), kg“105.3 (23.5)”“99.8 (20.2)”
Waist circumference, mean (SD), cm“118.2 (15.8)”“116.4 (12.6)”
BMI, mean (SD), kg/m2“37.1 (7.1)”“35.7 (6.2)”
BMI 27 to less than 30 kg/m2“13%”“22%”
BMI 30 to less than 35 kg/m2“32%”“34%”
BMI 35 to less than 40 kg/m2“26%”“22%”
BMI 40 kg/m2 or higher“29%”“22%”
Age distribution compared with NHANES
Age group, yearsVANQUISH-2 (N=1013)NHANES
18 to 34“3%”“5%”
35 to 44“11%”“8%”
45 to 54“22%”“16%”
55 to 64“34%”“33%”
65 to 74“25%”“26%”
75 or older“6%”“12%”
Race and ethnicity, prior GLP-1 receptor agonist exposure, and diabetes duration
CharacteristicVANQUISH-2 (N=1013)
Non-Hispanic White“43%”
Hispanic or Latino“29%”
Non-Hispanic Black“20%”
Non-Hispanic Asian“4%”
Other“3%”
Prior exposure to a GLP-1 receptor agonist“21%”
Time since type 2 diabetes diagnosis, mean (SD), years“10.3 (8.1)”
Baseline obesity complications compared with NHANES
ComplicationVANQUISH-2 (N=1013)NHANES
Hypertension“67%”“79%”
Dyslipidemia“66%”“89%”
Sleep apnea“25%”“NHANES comparator not available for sleep apnea.”
Osteoarthritis“22%”“31%”
Asthma“11%”“16%”
Coronary artery disease“8%”“17%”
Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary: limitations evident from the available VANQUISH-2 documents

VANQUISH-2 is ongoing, with primary completion estimated for July 2027, data expected in the second half of 2027, and readout expected after VANQUISH-1, so no efficacy, patient-reported outcome, or safety result is available. All available information comes from the ClinicalTrials.gov record, company press releases, an investor presentation, company call and conference transcripts, a congress abstract and poster authored by company employees, and a baseline poster authored by company employees and study investigators; no peer-reviewed design or results publication was identified, and the ClinicalTrials.gov record has posted no results.

Enrollment fell short of the plan: the design poster planned approximately 1,122 participants (306 per arm and 204 in the 7.5 mg arm) and the initiation release targeted approximately 1100, while 1,013 participants were randomized (276 per arm and 185 in the 7.5 mg arm).

The 7.5 mg arm is the smallest, so estimates for that dose will be less precise. The trial enrolled adults with type 2 diabetes and HbA1c of 7% to 11% in the United States and Puerto Rico only; background therapy with DPP-4 inhibitors, amylin analogues, GLP-1 receptor agonists, and dual GLP-1/GIP receptor agonists was not permitted, while 21% of participants reported prior GLP-1 receptor agonist exposure. Participants had a mean BMI of 37.1 kg/m2 and a mean diabetes duration of 10.3 years, and the prevalence of obesity complications was lower than in the NHANES comparison population. The company describes the blinded discontinuation rate only qualitatively. The device changed during the trial, from vial and syringe to an autoinjector, and in July 2026 the company stated that “almost everybody” in VANQUISH-2 was using the autoinjector. The extension study is expected to report in 2028 and will not inform the primary 78-week analysis.

SUNRISE-1

Objective
Location and study date
Study design
FDA end-of-phase 2 meeting for the oral tablet
Eligibility criteria
Treatment
Study outcomes
Rationale for using percent change in body weight as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Analysis populations

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary

SUNRISE-1 had reported no results as of November 2026, and every leaf on disposition, baseline characteristics, efficacy, quality of life, and safety is empty. The design is known only from the ClinicalTrials.gov record, company press releases, an investor presentation, and transcripts of investor calls; no protocol, statistical analysis plan, or peer-reviewed design paper is available.

The registry and the company documents differ on status and on doses. The company announced the program's initiation on October 14, 2026, and its later documents describe the trials as “Underway”, while the registry record still lists the study as “Not yet recruiting” with an estimated start in November 2026. The registry describes the three active arms only as dose levels 1 to 3; the doses of 27.5 mg, 35 mg, and 55 mg are stated in company releases.

The registry record lists one primary outcome and no secondary outcomes, so the responder endpoints and exploratory endpoints (function, metabolic health, mental health, productivity) rest on company documents. The planned enrollment of 560 participants is about 75% smaller than the subcutaneous phase 3 program, a reduction the company attributes to reusing safety data from the subcutaneous trials, which the FDA accepted while noting “risks going from phase II to phase III”. The company states that the doses were chosen in part to lower “the tablet burden” and for gross margin, and gives no exposure-response analysis for them. The FDA's details from the end-of-phase 2 meeting are not public, and the company declined to describe them.

SUNRISE-2

Objective
Location and study date
Study design
FDA end-of-phase 2 meeting for the oral tablet
Eligibility criteria
Treatment
Study outcomes
Rationale for using percent change in body weight as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Analysis populations

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary

SUNRISE-2 had reported no results as of November 2026, and every leaf on disposition, baseline characteristics, efficacy, quality of life, and safety is empty. The design is known only from the ClinicalTrials.gov record, company press releases, an investor presentation, and transcripts of investor calls; no protocol, statistical analysis plan, or peer-reviewed design paper is available.

The registry and the company documents differ on status, doses, and population. The company announced the program's initiation on October 14, 2026, and its later documents describe the trials as “Underway”, while the registry record still lists the study as “Not yet recruiting” with an estimated start in November 2026. The registry describes the three active arms only as dose levels 1 to 3; the doses of 27.5 mg, 35 mg, and 55 mg are stated in company releases. The company describes participants as “obese or overweight”, while the registry's inclusion criteria are a body mass index of 27 kg/m2 or more with type 2 diabetes and an HbA1c of 7% to 11%.

The registry record lists one primary outcome and no secondary outcomes, so the responder endpoints and the exploratory endpoints rest on company documents, and neither source names HbA1c as an outcome. Participants treated with GLP-1 receptor agonists, dual GLP-1/GIP receptor agonists, DPP-4 inhibitors, or amylin analogues are excluded, and the registry names diet, exercise, and oral glucose-lowering agents as permitted background therapy. The planned enrollment of 560 participants per trial is about 75% smaller than the subcutaneous phase 3 program, a reduction the company attributes to reusing safety data from the subcutaneous trials, which the FDA accepted while noting “risks going from phase II to phase III”. The company states that the doses were chosen in part to lower “the tablet burden” and for gross margin. The FDA's details from the end-of-phase 2 meeting are not public, and the company declined to describe them. Primary completion is estimated 3 months later than for SUNRISE-1 (October 2028 against July 2028).

VENTURE

Objective
Location and study date
Registered study dates
FieldQuoted record
Study start (actual)“2023-08-31”
Primary completion (actual)“2024-02-27”
Study completion (actual)“2024-04-02”
Study design
Registered design and masking
FieldQuoted record
Allocation“Randomized”
Intervention model“Parallel Assignment”
Masking“Triple”
Eligibility criteria
Treatment
Study outcomes
Rationale for using percent change in body weight as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographic and clinical characteristics by dose arm, randomized population
CharacteristicPlacebo (n = 35)2.5 mg (n = 35)5.0 mg (n = 35)10 mg (n = 36)15 mg (n = 35)
Age, years, mean (SD)“47.6 (16.36)”View highlighted excerpt for this quote“49.7 (13.90)”View highlighted excerpt for this quote“51.8 (14.10)”View highlighted excerpt for this quote“47.1 (13.40)”View highlighted excerpt for this quote“51.3 (15.41)”View highlighted excerpt for this quote
Age 65 years or older, n (%)“4 (11.4)”View highlighted excerpt for this quote“8 (22.9)”View highlighted excerpt for this quote“8 (22.9)”View highlighted excerpt for this quote“4 (11.1)”View highlighted excerpt for this quote“8 (22.9)”View highlighted excerpt for this quote
Female, n (%)“29 (82.9)”View highlighted excerpt for this quote“27 (77.1)”View highlighted excerpt for this quote“23 (65.7)”View highlighted excerpt for this quote“24 (66.7)”View highlighted excerpt for this quote“27 (77.1)”View highlighted excerpt for this quote
White, n (%)“26 (74.3)”View highlighted excerpt for this quote“28 (80.0)”View highlighted excerpt for this quote“31 (88.6)”View highlighted excerpt for this quote“26 (72.2)”View highlighted excerpt for this quote“28 (80.0)”View highlighted excerpt for this quote
Black or African American, n (%)“8 (22.9)”View highlighted excerpt for this quote“7 (20.0)”View highlighted excerpt for this quote“2 (5.7)”View highlighted excerpt for this quote“10 (27.8)”View highlighted excerpt for this quote“6 (17.1)”View highlighted excerpt for this quote
Hispanic or Latino, n (%)“7 (20.0)”View highlighted excerpt for this quote“5 (14.3)”View highlighted excerpt for this quote“7 (20.0)”View highlighted excerpt for this quote“6 (16.7)”View highlighted excerpt for this quote“5 (14.3)”View highlighted excerpt for this quote
Weight, kg, mean (SD)“104.48 (22.18)”View highlighted excerpt for this quote“103.09 (19.01)”View highlighted excerpt for this quote“98.32 (13.18)”View highlighted excerpt for this quote“102.98 (18.27)”View highlighted excerpt for this quote“101.05 (18.91)”View highlighted excerpt for this quote
BMI, kg/m2, mean (SD)“38.88 (6.33)”View highlighted excerpt for this quote“38.03 (5.56)”View highlighted excerpt for this quote“35.86 (4.03)”View highlighted excerpt for this quote“36.62 (4.18)”View highlighted excerpt for this quote“36.63 (5.25)”View highlighted excerpt for this quote
Prediabetes, n (%)“14 (40.0)”View highlighted excerpt for this quote“21 (60.0)”View highlighted excerpt for this quote“21 (60.0)”View highlighted excerpt for this quote“16 (44.4)”View highlighted excerpt for this quote“16 (45.7)”View highlighted excerpt for this quote
Metabolic syndrome at baseline by dose arm
ArmMetS at baseline, n/N (%)
Placebo“18/34 (53)”
VK2735 2.5 mg“21/35 (60)”
VK2735 5.0 mg“22/35 (63)”
VK2735 10 mg“14/35 (40)”
VK2735 15 mg“13/35 (37)”
All VK2735“70/140 (50)”
Baseline cardiovascular risk factors in the cardiovascular risk analysis subset
CharacteristicPlacebo (n=27)All VK2735 (n=116)
Age, years, mean (SD)“51.9 (12.2)”“51.8 (12.1)”
Class 3 obesity, BMI 40 or higher, n (%)“13 (48.2)”“27 (23.3)”
Current smoker, n (%)“2 (7.4)”“15 (12.9)”
Current statin user, n (%)“5 (18.5)”“30 (25.9)”
Current hypertension medication user, n (%)“12 (44.4)”“40 (34.5)”
Efficacy results
Primary endpoint: percent change in body weight at week 13 by dose, mITT population
Categorical weight reduction of at least 5%, 10%, and 15% at week 13 by dose
Threshold and statisticPlacebo (n = 34)2.5 mg (n = 35)5.0 mg (n = 35)10 mg (n = 35)15 mg (n = 35)
At least 5% reduction, n (%)“4 (11.5)”View highlighted excerpt for this quote“28 (80.8)”View highlighted excerpt for this quote“34 (97.0)”View highlighted excerpt for this quote“33 (93.8)”View highlighted excerpt for this quote“35 (100)”View highlighted excerpt for this quote
At least 5%, odds ratio vs placebo (95% CI)Not applicable“26.7 (6.9, 103.2)”View highlighted excerpt for this quote“148.9 (20.8, > 999.9)”View highlighted excerpt for this quote“84.6 (15.6, 457.2)”View highlighted excerpt for this quote“454.1 (23.3, > 999.9)”View highlighted excerpt for this quote
At least 10% reduction, n (%)“1 (3.0)”View highlighted excerpt for this quote“14 (40.1)”View highlighted excerpt for this quote“23 (65.1)”View highlighted excerpt for this quote“25 (70.4)”View highlighted excerpt for this quote“31 (89.1)”View highlighted excerpt for this quote
At least 10%, odds ratio vs placebo (95% CI)Not applicable“23.6 (2.8, 197.5)”View highlighted excerpt for this quote“60.2 (7.1, 509.3)”View highlighted excerpt for this quote“91.5 (10.4, 806.8)”View highlighted excerpt for this quote“315.5 (30.6, > 999.9)”View highlighted excerpt for this quote
At least 10%, p value vs placeboNot applicable“0.0036”View highlighted excerpt for this quote“0.0002”View highlighted excerpt for this quote“< 0.0001”View highlighted excerpt for this quote“< 0.0001”View highlighted excerpt for this quote
At least 15% reduction, n (%)“0”View highlighted excerpt for this quote“4 (12.8)”View highlighted excerpt for this quote“4 (11.6)”View highlighted excerpt for this quote“11 (31.2)”View highlighted excerpt for this quote“15 (41.5)”View highlighted excerpt for this quote
At least 15%, odds ratio vs placebo (95% CI)Not applicable“11.2 (0.5, 228.2)”View highlighted excerpt for this quote“9.1 (0.4, 188.6)”View highlighted excerpt for this quote“35.9 (1.9, 677.1)”View highlighted excerpt for this quote“52.3 (2.8, 982.7)”View highlighted excerpt for this quote
At least 15%, p value vs placeboNot applicable“0.1163”View highlighted excerpt for this quote“0.1533”View highlighted excerpt for this quote“0.0169”View highlighted excerpt for this quote“0.0082”View highlighted excerpt for this quote
Topline release: placebo-adjusted weight change and 10% responders by dose
MeasurePlacebo (n=34)2.5 mg (n=35)5 mg (n=35)10 mg (n=35)15 mg (n=35)
Placebo-adjusted mean percent change from baselineNot applicable“-7.4 %”“-9.2 %”“-11.3 %”“-13.1 %”
Percent reporting at least 10% weight loss“4 %”“39 %”“62 %”“70 %”“88 %”
Off-treatment follow-up: weight loss persisting 4 and 7 weeks after the last dose
Time after final dose2.5 mg (n=17)5 mg (n=17)10 mg (n=18)15 mg (n=11)Combined VK2735 arms
Proportion of weight loss maintained, four weeks post final dose“98 %”“92 %”“92 %”“96 %”“94 %”
Proportion of weight loss maintained, seven weeks post final dose“91 %”“82 %”“75 %”“87 %”“83 %”
Pharmacokinetics in the follow-up subset
Representative PK parameter, VK2735 5.0 mgValue
Cmax, ng/mL“1,120”
AUC0-168, ng*h/mL“158,000”
Half-life, h“171”
Glycemic status: shift from prediabetes to normoglycemia and change in glucose and HbA1c
MeasurePlacebo (n = 35)2.5 mg (n = 35)5.0 mg (n = 35)10 mg (n = 36)15 mg (n = 35)
Prediabetes at baseline, n“14”View highlighted excerpt for this quote“21”View highlighted excerpt for this quote“21”View highlighted excerpt for this quote“16”View highlighted excerpt for this quote“16”View highlighted excerpt for this quote
Shift to normoglycemic, n (%)“4 (28.6)”View highlighted excerpt for this quote“17 (81.0)”View highlighted excerpt for this quote“16 (76.2)”View highlighted excerpt for this quote“10 (62.5)”View highlighted excerpt for this quote“15 (93.8)”View highlighted excerpt for this quote
Shift to diabetes, n (%)“1 (7.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Fasting glucose, mg/dL, baseline mean (SD)“99.37 (9.932)”View highlighted excerpt for this quote“100.31 (9.320)”View highlighted excerpt for this quote“99.77 (9.478)”View highlighted excerpt for this quote“97.97 (8.687)”View highlighted excerpt for this quote“99.06 (7.685)”View highlighted excerpt for this quote
Fasting glucose, mg/dL, change from baseline, LS mean (SE)“−0.37 (1.475)”View highlighted excerpt for this quote“−10.66 (1.439)”View highlighted excerpt for this quote“−10.23 (1.424)”View highlighted excerpt for this quote“−9.46 (1.424)”View highlighted excerpt for this quote“−10.85 (1.456)”View highlighted excerpt for this quote
HbA1c, %, baseline mean (SD)“5.49 (0.361)”View highlighted excerpt for this quote“5.51 (0.360)”View highlighted excerpt for this quote“5.43 (0.399)”View highlighted excerpt for this quote“5.50 (0.357)”View highlighted excerpt for this quote“5.50 (0.312)”View highlighted excerpt for this quote
HbA1c, %, change from baseline, LS mean (SE)“0.03 (0.041)”View highlighted excerpt for this quote“−0.29 (0.040)”View highlighted excerpt for this quote“−0.27 (0.040)”View highlighted excerpt for this quote“−0.27 (0.039)”View highlighted excerpt for this quote“−0.36 (0.040)”View highlighted excerpt for this quote
Blood pressure change at week 13 by dose
MeasurePlacebo (n = 35)2.5 mg (n = 35)5.0 mg (n = 35)10 mg (n = 36)15 mg (n = 35)
Systolic blood pressure, mmHg, baseline mean (SD)“125.10 (13.963)”View highlighted excerpt for this quote“126.20 (14.754)”View highlighted excerpt for this quote“128.60 (15.253)”View highlighted excerpt for this quote“122.64 (13.764)”View highlighted excerpt for this quote“123.36 (14.531)”View highlighted excerpt for this quote
Systolic blood pressure, mmHg, change from baseline, LS mean (SE)“−4.20 (1.993)”View highlighted excerpt for this quote“−6.87 (1.906)”View highlighted excerpt for this quote“−6.71 (1.931)”View highlighted excerpt for this quote“−7.04 (1.936)”View highlighted excerpt for this quote“−10.97 (2.000)”View highlighted excerpt for this quote
Diastolic blood pressure, mmHg, baseline mean (SD)“80.93 (9.169)”View highlighted excerpt for this quote“81.56 (9.491)”View highlighted excerpt for this quote“82.91 (7.904)”View highlighted excerpt for this quote“79.00 (9.420)”View highlighted excerpt for this quote“78.39 (7.332)”View highlighted excerpt for this quote
Diastolic blood pressure, mmHg, change from baseline, LS mean (SE)“−1.68 (1.286)”View highlighted excerpt for this quote“−3.27 (1.229)”View highlighted excerpt for this quote“−4.34 (1.246)”View highlighted excerpt for this quote“−2.37 (1.247)”View highlighted excerpt for this quote“−5.16 (1.290)”View highlighted excerpt for this quote
Lipids and other cardiometabolic parameters, combined VK2735 arms versus placebo
ParameterMean difference, VK2735 compared with placeboStandardized mean difference (95% CI)
Total cholesterol, mg/dL“–8.03”“–0.26 (–0.75, 0.22)”
Triglycerides, mg/dL“–11.90”“–0.22 (–0.70, 0.27)”
LDL, mg/dL“–3.98”“–0.14 (–0.63, 0.34)”
HbA1c, %“–0.32”“–1.49 (–2.01, –0.97)”
BMI, kg/m²“–3.52”“–2.32 (–2.90, –1.75)”
SBP, mmHg“–2.40”“–0.20 (–0.69, 0.28)”
Predicted 10-year cardiovascular risk at week 13, post hoc analysis
Predicted 10-year riskLS mean difference in percent change from baseline, VK2735 vs placebo (95% CI)P value
Cardiovascular disease“–4.14 (–17.22, 8.94)”“.532”
Atherosclerotic cardiovascular disease“–6.67 (–19.44, 6.09)”“.303”
Heart failure“–16.21 (–27.37, –5.06)”“.005”
BMI category shifts from baseline to week 13, exploratory analysis
Baseline category and transitionVK2735 combinedPlacebo
Class III obesity at baseline, n“n=35”“n=15”
Class III, transitioning to Class II“57 %”“13 %”
Class III, transitioning to Class I“11 %”“0 %”
Class III, no change in obesity class“31 %”“87 %”
Class II obesity at baseline, n“n=51”“n=10”
Class II, transitioning to Class I“80 %”“20 %”
Class II, transitioning to overweight“2 %”“0 %”
Class II, no change in obesity class“18 %”“80 %”
Class I obesity at baseline, n“n=46”“n=8”
Class I, transitioning to overweight“65 %”“12 %”
Class I, transitioning to normal weight“9 %”“0 %”
Class I, no change in obesity class“26 %”“75%”
Overweight at baseline, n“n=8”“n=1”
Overweight, transitioning to normal weight“50 %”“0 %”
Cardiometabolic markers by BMI category change among VK2735-treated participants
Marker, mean (SD)Baseline (N=124)Change with at least one BMI category improvement (N=89)Change with no BMI category change (N=35)
Hemoglobin A1C, %“5.49 (0.36)”“-0.34 (0.25)”“-0.25 (0.17)”
Glucose, mg/dL“99.8 (8.77)”“-12.4 (9.69)”“-10.1 (8.56)”
Triglycerides, mg/dL“122.1 (62.16)”“-20.1 (56.76)”“-2.2 (52.40)”
Waist circumference, cm“112.7 (11.34)”“-10.1 (5.90)”“-7.7 (4.24)”
Systolic blood pressure, mmHg“124.5 (14.53)”“-9.0 (12.26)”“-6.0 (13.47)”
Diastolic blood pressure, mmHg“80.1 (8.69)”“-4.2 (8.27)”“-2.8 (8.97)”
LDL cholesterol, mg/dL“116.7 (33.12)”“-12.3 (27.61)”“-6.9 (23.45)”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Overall treatment-emergent adverse events and severity
Discontinuation due to adverse events by dose
Gastrointestinal adverse events by dose, all causality
Preferred term, n (%)Placebo (n = 35)2.5 mg (n = 35)5.0 mg (n = 35)10 mg (n = 35)15 mg (n = 35)
Gastrointestinal disorders, any“13 (37)”View highlighted excerpt for this quote“18 (51)”View highlighted excerpt for this quote“23 (66)”View highlighted excerpt for this quote“25 (71)”View highlighted excerpt for this quote“29 (83)”View highlighted excerpt for this quote
Nausea“7 (20)”View highlighted excerpt for this quote“9 (26)”View highlighted excerpt for this quote“16 (46)”View highlighted excerpt for this quote“13 (37)”View highlighted excerpt for this quote“22 (63)”View highlighted excerpt for this quote
Constipation“4 (11)”View highlighted excerpt for this quote“7 (20)”View highlighted excerpt for this quote“10 (29)”View highlighted excerpt for this quote“9 (26)”View highlighted excerpt for this quote“10 (29)”View highlighted excerpt for this quote
Diarrhea“3 (9)”View highlighted excerpt for this quote“11 (31)”View highlighted excerpt for this quote“6 (17)”View highlighted excerpt for this quote“7 (20)”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote
Vomiting“0”View highlighted excerpt for this quote“3 (9)”View highlighted excerpt for this quote“6 (17)”View highlighted excerpt for this quote“6 (17)”View highlighted excerpt for this quote“10 (29)”View highlighted excerpt for this quote
Gastroesophageal reflux disease“1 (3)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“5 (14)”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote“6 (17)”View highlighted excerpt for this quote
Abdominal pain“1 (3)”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote
Eructation“0”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (9)”View highlighted excerpt for this quote
Decreased appetite“0”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“5 (14)”View highlighted excerpt for this quote“9 (26)”View highlighted excerpt for this quote“6 (17)”View highlighted excerpt for this quote
Drug-related gastrointestinal adverse events by severity and dose
Event and severity, n (%)Placebo (n = 35)2.5 mg (n = 35)5.0 mg (n = 35)10 mg (n = 35)15 mg (n = 35)
Any gastrointestinal disorder, mild“8 (23)”View highlighted excerpt for this quote“8 (23)”View highlighted excerpt for this quote“14 (40)”View highlighted excerpt for this quote“13 (37)”View highlighted excerpt for this quote“16 (46)”View highlighted excerpt for this quote
Any gastrointestinal disorder, moderate“4 (11)”View highlighted excerpt for this quote“7 (20)”View highlighted excerpt for this quote“9 (26)”View highlighted excerpt for this quote“7 (20)”View highlighted excerpt for this quote“10 (29)”View highlighted excerpt for this quote
Any gastrointestinal disorder, severe“0”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“3 (9)”View highlighted excerpt for this quote
Nausea, mild“7 (20)”View highlighted excerpt for this quote“5 (14)”View highlighted excerpt for this quote“11 (31)”View highlighted excerpt for this quote“8 (23)”View highlighted excerpt for this quote“15 (43)”View highlighted excerpt for this quote
Nausea, moderate“0”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“5 (14)”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote“7 (20)”View highlighted excerpt for this quote
Constipation, mild“2 (6)”View highlighted excerpt for this quote“3 (9)”View highlighted excerpt for this quote“8 (23)”View highlighted excerpt for this quote“6 (17)”View highlighted excerpt for this quote“9 (26)”View highlighted excerpt for this quote
Constipation, moderate“2 (6)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote
Vomiting, mild“0”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote“5 (14)”View highlighted excerpt for this quote“5 (14)”View highlighted excerpt for this quote
Vomiting, moderate“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (9)”View highlighted excerpt for this quote
Diarrhea, mild“2 (6)”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote“5 (14)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote
Diarrhea, moderate“0”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (9)”View highlighted excerpt for this quote
Adverse events of special interest: pancreatitis, gallbladder events, and injection site reactions
Heart rate and blood pressure as reported on the 2024 congress poster
Vital signPlacebo2.5 mg5 mg10 mg15 mg
Heart rate, bpm, baseline“65.7”“63.5”“66.9”“64.3”“63.9”
Heart rate, bpm, mean change at week 13“4.4”“3.8”“5.0”“10.8”“7.1”
Systolic blood pressure, mmHg, mean change at week 13“-4.4”“-7.4”“-8.8”“-5.4”“-9.6”
Diastolic blood pressure, mmHg, mean change at week 13“-2.2”“-3.7”“-5.5”“-1.5”“-4.3”
Other selected adverse events by dose: hypotension, dizziness, fatigue, lipase, and hyperthyroidism
Preferred term, n (%)Placebo (n = 35)2.5 mg (n = 35)5.0 mg (n = 35)10 mg (n = 35)15 mg (n = 35)
Hypotension“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote
Dizziness“1 (3)”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote
Fatigue“1 (3)”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“5 (14)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote
Headache“4 (11)”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote
Lipase increased“0”View highlighted excerpt for this quote“1 (3)”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Hyperthyroidism“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (6)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Study limitations
Summary: limitations of the VENTURE evidence

VENTURE was a phase 2 dose-finding trial of 13 weeks of treatment in 176 randomized participants, about 35 per arm, conducted at 20 United States sites. The authors state that it was “limited in size and duration” and “not powered to determine statistical significance for differences between treatment groups for most parameters.” The sample size calculation of 29 participants per arm was based on a two-sample t-test. A 13-week result does not address the FDA draft guidance benchmark, which assesses effectiveness after 1 year of treatment at the maintenance dosage. The topline release reported no weight-loss plateau at week 13, and the authors state that “Maximal therapeutic levels were likely not yet achieved in this limited duration study.”

People with diabetes were excluded, BMI above 50 kg/m2 was excluded, and the randomized population was mostly female and White, with between 65.7% and 82.9% female and between 72.2% and 88.6% White participants per arm. The 15 mg arm started at 5.0 mg while the other arms started at 2.5 mg, and the authors state that the “titration schedule and dosing, will be changed to optimize tolerability in future studies.”

The primary analysis was a mixed model for repeated measures in the modified intent-to-treat population (174 participants), with assessments more than 9 days after treatment discontinuation set to missing and data assumed missing at random. This corresponds to an on-treatment estimand; no treatment-policy analysis that retains off-treatment weights was reported. Off-treatment weight data at weeks 16 and 19 were reported only for a pharmacokinetic subset of 75 participants (63 VK2735, 12 placebo). Responder analyses, which the FDA draft guidance states may “inappropriately exaggerate treatment effects”, were secondary endpoints.

Reported figures differ between documents. The topline release reported 23 participants (13%) discontinuing treatment and 10% responder proportions of 4%, 39%, 62%, 70%, and 88%, while the publication reported 24 of 176 (14%) and 3.0%, 40.1%, 65.1%, 70.4%, and 89.1%. Baseline heart rate on the 2024 poster (63.5 to 66.9 bpm) differs from the publication (69.3 to 74.2 bpm), as does the week 13 heart rate change (3.8 to 10.8 bpm versus 3.3 to 9.3 bpm in active arms). Mean heart rate increased by up to 9.3 bpm in the 10 mg arm versus 1.4 bpm with placebo in the publication. Treatment discontinuation due to adverse events rose with dose, from 1 of 35 (3%) at 2.5 mg to 7 of 35 (20%) at 15 mg, with none on placebo.

The metabolic syndrome, BMI category, and predicted cardiovascular risk analyses were exploratory or post hoc, reported in company releases and congress posters without peer review, used observed values without imputation, and reported no adjustment for multiplicity. The cardiovascular risk subset comprised 143 participants, of whom 110 (20 placebo, 90 VK2735) entered the risk model, and all authors of that poster are company employees. No health-related quality of life or patient-reported outcome was reported. The trial was funded by Viking Therapeutics, and every author of the publication was a site investigator or a company employee. No results are posted on ClinicalTrials.gov.

VENTURE-Oral dosing

Objective
Location and study date
Registry study dates
MilestoneRegistry entry
Study start (actual)“2024-12-18”
Primary completion (actual)“2025-06-24”
Study completion (actual)“2025-08-15”
First posted“2025-02-14”
Last update posted“2025-10-06”
Study design
Registry design and masking
Design elementRegistry entry
Allocation“Randomized”
Intervention model“Parallel Assignment”
Masking“Triple”
Primary purpose“Treatment”
Eligibility criteria
Treatment
Study outcomes
Rationale for using percent change in body weight as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed by arm
ArmEfficacy populationSafety population
Placebo“(n=40)”“(n=40)”
VK2735 15 mg“(n=40)”“(n=40)”
VK2735 30 mg“(n=40)”“(n=40)”
VK2735 60 mg“(n=38)”“(n=40)”
VK2735 90 mg“(n=39)”“(n=40)”
VK2735 120 mg“(n=39)”“(n=40)”
Exploratory maintenance cohort“Efficacy population (n=39)”Not reported
Description of analysis sets
Sample size calculation and multiplicity control

No evidence found.

Estimand and handling of missing data

No evidence found.

Results
Participant disposition
Treatment and study discontinuation by dose
CategoryPlaceboVK2735 15 mgVK2735 30 mgVK2735 60 mgVK2735 90 mgVK2735 120 mg
Participants“(n=40)”“(n=40)”“(n=40)”“(n=40)”“(n=40)”“(n=40)”
Discontinued treatment early, n (%)“7 (18)”“8 (20)”“8 (20)”“11 (28)”“10 (25)”“15 (38)”
TEAE leading to treatment discontinuation, n (%)“5 (13)”“2 (5)”“5 (13)”“7 (18)”“8 (20)”“12 (30)”
Drug-related TEAE leading to treatment discontinuation, n (%)“3 (8)”“1 (3)”“5 (13)”“6 (15)”“8 (20)”“11 (28)”
Discontinued study early, n (%)“2 (5)”“4 (10)”“5 (13)”“5 (13)”“3 (8)”“5 (13)”
TEAE leading to study discontinuation, n (%)“1 (3)”“0”“1 (3)”“0”“1 (3)”“0”
Drug-related TEAE leading to study discontinuation, n (%)“1 (3)”“0”“1 (3)”“0”“1 (3)”“0”
Baseline characteristics
Baseline characteristics by arm, safety population
CharacteristicPlaceboVK2735 15 mgVK2735 30 mgVK2735 60 mgVK2735 90 mgVK2735 120 mg
Participants“(n=40)”“(n=40)”“(n=40)”“(n=40)”“(n=40)”“(n=40)”
Age, mean years“51”“54”“53”“49”“52”“50”
Sex, % male:female“30:70”“20:80”“45:55”“15:85”“32:68”“28:72”
White, %“85”“80”“73”“68”“88”“83”
Non-Hispanic, %“70”“78”“80”“85”“75”“73”
Weight, mean kg“105”“99”“103”“103”“103”“102”
BMI, mean kg/m2“38”“37”“35”“37”“37”“37”
Prediabetes, %“53”“45”“60”“38”“68”“63”
Mean baseline body weight by arm, efficacy population
ArmMean baseline body weight
Placebo“105.2 kg”
VK2735 15 mg“99.0 kg”
VK2735 30 mg“102.9 kg”
VK2735 60 mg“102.8 kg”
VK2735 90 mg“103.4 kg”
VK2735 120 mg“101.9 kg”
Exploratory maintenance cohort“102.8 kg”
Efficacy results
Primary and key secondary endpoints at week 13 by dose
MeasurePlaceboVK2735 15 mgVK2735 30 mgVK2735 60 mgVK2735 90 mgVK2735 120 mg
Participants, efficacy population“(n=40)”“(n=40)”“(n=40)”“(n=38)”“(n=39)”“(n=39)”
Mean change from baseline body weight, least squares mean“-1.3 kg”“-2.2 kg”“-7.1 kg”“-8.8 kg”“-11.5 kg”“-12.1 kg”
Mean percent change from baseline, least squares mean“-1.3 %”“-2.3 %”“-7.0 %”“-8.7 %”“-11.1 %”“-12.2 %”
p-value versus baseline“-”“0.0057”“<0.0001”“<0.0001”“<0.0001”“<0.0001”
Placebo-adjusted mean percent change from baseline“-”“-1.0 %”“-5.7 %”“-7.4 %”“-9.8 %”“-10.9 %”
p-value versus placebo, percent change“-”“-”“<0.0001”“<0.0001”“<0.0001”“<0.0001”
Percent reporting at least 10% weight loss“5 %”“8 %”“35 %”“40 %”“59 %”“80 %”
p-value versus placebo, at least 10% weight loss“-”“-”“<0.01”“0.0017”“< 0.0001”“<0.0001”
Weight change at week 16, three weeks after the last dose
ArmWeek 16 change from baseline, least squares mean
Placebo“-1.4%”
VK2735 30 mg“-6.7%”
VK2735 30/60 mg (60 mg arm)“-8.2%”
VK2735 30/60/90 mg (90 mg arm)“-10.3%”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Treatment-emergent adverse events by dose
CategoryPlaceboVK2735 15 mgVK2735 30 mgVK2735 60 mgVK2735 90 mgVK2735 120 mg
Participants“(n=40)”“(n=40)”“(n=40)”“(n=40)”“(n=40)”“(n=40)”
TEAEs, n (%)“34 (85)”“35 (88)”“33 (83)”“33 (83)”“37 (93)”“36 (90)”
Treatment-related TEAEs, n (%)“27 (68)”“28 (70)”“30 (75)”“31 (78)”“37 (93)”“34 (85)”
Common drug-related gastrointestinal adverse events by dose
Drug-related gastrointestinal adverse events by severity grade
SeverityPlaceboVK2735 15 mgVK2735 30 mgVK2735 60 mgVK2735 90 mgVK2735 120 mg
Any drug-related GI TEAE, mild, grade 1, n (%)“17 (43)”“18 (45)”“16 (40)”“18 (45)”“21 (53)”“18 (45)”
Any drug-related GI TEAE, moderate, grade 2, n (%)“6 (15)”“6 (15)”“11 (28)”“12 (30)”“13 (33)”“11 (28)”
Any drug-related GI TEAE, severe, grade 3, n (%)“1 (3)”“0”“0”“0”“0”“2 (5)”
Nausea, mild/moderate/severe, % of participants“40/8/0”“30/5/0”“38/18/0”“33/20/0”“55/18/0”“38/18/5”
Constipation, mild/moderate/severe, % of participants“13/10/0”“13/10/0”“10/10/0”“20/10/0”“33/10/0”“25/3/0”
Vomiting, mild/moderate/severe, % of participants“3/8/0”“5/0/0”“8/8/0”“18/3/0”“30/5/0”“15/15/5”
Diarrhea, mild/moderate/severe, % of participants“10/0/3”“5/0/0”“8/0/0”“15/0/0”“10/5/0”“15/10/0”
Laboratory values, vital signs, and heart rate

No evidence found.

Study limitations
Summary: limitations of the VENTURE-Oral Dosing evidence

Treatment lasted 13 weeks, and about 40 participants were randomized to each of 7 arms (280 in total). The release reports that weight loss showed “no plateau” at 13 weeks, so the maximal effect of each dose is not known from these data; FDA draft guidance asks that phase 2 duration capture “maximal or near-maximal” effects and sets its efficacy benchmark after 1 year of treatment. Week 16 off-treatment values were reported only for placebo and the 30, 60, and 90 mg arms.

Results are available only in company press releases, a sponsor-funded congress poster, a corporate presentation, and investor call transcripts. No peer-reviewed publication was identified, and the registry record has no posted results. Pharmacokinetic results, a stated objective, have not been reported. No document describes the sample size calculation, control of multiplicity, the estimand, or the handling of missing data.

Treatment discontinuation was 18% with placebo and ranged from 20% (15 mg and 30 mg) to 38% (120 mg) across the fixed-dose arms; discontinuation of treatment due to a TEAE was 13% with placebo and 30% with 120 mg. The release describes discontinuation due to adverse events as “low and well-balanced”. Its pooled VK2735 rates (28% for any treatment discontinuation and 20% for discontinuation due to an adverse event) are higher than the totals of the 5 fixed-dose arms in the per-arm tables (52 of 200, 26%, and 34 of 200, 17%); no document states whether the pooled rates include the exploratory maintenance cohort, whose disposition and adverse events are reported only as qualitative statements on the investor call. Efficacy was analyzed in a modified population that required a post-baseline weight, with 38 or 39 participants in the 60, 90, and 120 mg arms.

The fixed-dose arms were titrated in 2-week steps starting at 30 mg, every participant took 4 tablets daily after an overnight fast, and no food-effect study had been done. The doses later chosen for the phase 3 SUNRISE trials (27.5, 35, and 55 mg) were not tested as fixed arms. Nausea was reported by 48% of placebo recipients, and the company noted on its investor call that placebo adverse event rates were higher than in the earlier study. Participants with diabetes were excluded, all 15 sites were in the United States, and most participants were White, non-Hispanic, and female.

The documents differ on some points. The ECO release names the poster's trial the “VENTURE-2 Study” and calls the study “Phase 2a”. A corporate presentation note states “Baseline BMI ≥30 in all subjects” although eligibility allowed a BMI of 27 kg/m2 or higher with a comorbidity. The poster footnote on serious adverse events states “Three participants” and then lists one participant in the 60 mg arm and “1 pt with dehydration and 2 pts with nausea/vomiting” in the 120 mg arm. A third-party transcript of a November 2025 presentation records the maintenance cohort ending at 8.2% weight loss, while the release reports 9.2%. The registry arms are labeled “Dose #1” to “Dose #6” without the doses.

VK2735-102 part 1 subcutaneous maintenance

Objective
Location and study date
Study dates and United States sites in the ClinicalTrials.gov record
FieldRegistry value
Study start (actual)“2025-11-18”
Primary completion (estimated)“2027-05”
Study completion (estimated)“2027-07”
First posted“2026-09-24”
Site 1“Viking Clinical Site #001”
Site 1 city“Lake Forest”
Site 2“Viking Clinical Site #002”
Site 2 city“Miami”
Study design
Eligibility criteria
Age range in the ClinicalTrials.gov record
FieldRegistry value
Minimum age“18 Years”
Maximum age“60 Years”
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed in the induction efficacy population
GroupParticipants analyzed at week 21
Placebo“(n=15)”
VK2735 15 mg weekly“(n=14)”
VK2735 17.5 mg weekly“(n=118)”
VK2735 20 mg weekly“(n=15)”
VK2735 22.5 mg weekly“(n=14)”
Participants analyzed in the maintenance period
GroupEfficacy populationSafety population
Placebo after 17.5 mg weekly“(n=27)”“(n=27)”
VK2735 combined every other week“(n=37)”“(n=37)”
VK2735 combined monthly“QM (n=65)”“QM (n=66)”
Description of analysis sets
Results
Participant disposition
Discontinuations during the 21-week induction period
OutcomePlacebo (n=15)VK2735 combined (n=166)15 mg weekly (n=15)17.5 mg weekly (n=121)20 mg weekly (n=15)22.5 mg weekly (n=15)
Discontinued treatment early“0 (0%)”“22 (13%)”“2 (13%)”“15 (12%)”“1 (7%)”“4 (27%)”
Discontinued treatment due to adverse event“0 (0%)”“1 (1%)”“0 (0%)”“1 (1%)”“0 (0%)”“0 (0%)”
Discontinuations during the every-other-week maintenance period
OutcomePlacebo (n=27)VK2735 combined (n=37)5.0 mg (n=12)7.5 mg (n=13)10.0 mg (n=12)
Discontinued treatment early“0 (0 %)”“1 (3 %)”“0 (0 %)”“0 (0 %)”“1 (8 %)”
Discontinued treatment due to adverse event“0 (0 %)”“1 (3 %)”“0 (0 %)”“0 (0 %)”“1 (8 %)”
Discontinuations during the monthly maintenance period
OutcomePlacebo (n=27)VK2735 combined (n=66)10 mg (n=16)15 mg (n=14)17.5 mg (n=11)20 mg (n=14)22.5 mg (n=11)
Discontinued treatment early“0 (0 %)”“3 (5 %)”“0 (0 %)”“1 (7 %)”“1 (9 %)”“1 (7 %)”“0 (0 %)”
Discontinued treatment due to adverse event“0 (0 %)”“1 (2 %)”“0 (0 %)”“0 (0 %)”“0 (0 %)”“1 (7 %)”“0 (0 %)”
Baseline characteristics
Mean baseline body weight by induction dose
GroupMean baseline body weight
Placebo (n=15)“100.0 kg”
VK2735 15 mg weekly (n=14)“108.4 kg”
VK2735 17.5 mg weekly (n=118)“95.9 kg”
VK2735 20 mg weekly (n=15)“101.9 kg”
VK2735 22.5 mg weekly (n=14)“103.0 kg”
Efficacy results
Change in body weight after 21 weeks of weekly dosing
MeasurePlacebo (n=15)15 mg weekly (n=14)17.5 mg weekly (n=118)20 mg weekly (n=15)22.5 mg weekly (n=14)
Mean change from baseline body weight“-0.1 kg”“-17.0 kg”“-17.0 kg”“-18.6 kg”“-17.2 kg”
Mean percent change from baseline“-0.1 %”“-16.3 %”“-17.8 %”“-18.7 %”“-17.1 %”
Placebo-adjusted mean percent change from baseline“-”“-16.2 %”“-17.7 %”“-18.6 %”“-17.0 %”
p-value vs. placebo“-”“<0.0001”“<0.0001”“<0.0001”“<0.0001”
Percentage of week 21 weight loss maintained at week 33 with every-other-week dosing
MeasurePlacebo (n=27)Combined every other week (n=37)17.5 mg weekly to 5.0 mg every other week (n=12)15.0 mg weekly to 7.5 mg every other week (n=13)17.5 mg weekly to 10.0 mg every other week (n=12)
Mean percentage of week 21 weight loss maintained at week 33“61 %”“90 %”“83 %”“90 %”“97 %”
p-value vs. placebo“-”“p<0.0001”“0.004”“<0.0001”“<0.0001”
Percentage of week 21 weight loss maintained at week 33 with monthly dosing
MeasurePlacebo (n=27)Combined monthly (n=65)17.5 mg weekly to 10 mg monthly (n=16)17.5 mg weekly to 15 mg monthly (n=14)17.5 mg weekly to 17.5 mg monthly (n=11)20 mg weekly to 20 mg monthly (n=14)22.5 mg weekly to 22.5 mg monthly (n=10)
Mean percentage of week 21 weight loss maintained at week 33“61 %”“85 %”“82 %”“84 %”“90 %”“86 %”“85 %”
p-value vs. placebo“-”“<0.0001”“0.0016”“0.0012”“0.0002”“0.0005”“0.0024”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse events and gastrointestinal adverse events through week 21
Adverse events after transition to every-other-week dosing
Adverse events after transition to monthly dosing
Study limitations
Summary: study limitations

Part 1 of the VK2735-102 study was a phase 1 trial in which 180 otherwise healthy adults with a body mass index of at least 30 kg/m2 and no diabetes were randomized across 11 treatment groups; the registry age range was 18 to 60 years. The primary endpoint was the incidence of treatment-emergent adverse events, and all body weight endpoints were exploratory. The induction placebo group had 15 participants, while 118 of the 176 participants in the induction efficacy population received 17.5 mg weekly. Each maintenance regimen had 10 to 16 participants in the efficacy population, the maintenance period lasted 12 weeks, and the maintenance placebo group (27 participants) consisted of participants switched from 17.5 mg weekly to placebo at week 21. The result for the 22.5 mg monthly cohort excludes one participant with a “maintenance effect >2.5x standard deviation from cohort mean”. During induction, 22 of 166 VK2735-treated participants (13%) discontinued treatment early, including 4 of 15 (27%) at 22.5 mg weekly, compared with 0 of 15 receiving placebo; the induction safety population (181 participants) is 1 larger than the reported number randomized (180). The design changed after initiation: the releases of October 2025 and January 2026 and the Form 10-K of February 2026 described a 19-week induction, maintenance options that included “daily oral doses” and “weekly oral doses”, and an end of study at week 31, whereas the reported Part 1 used a 21-week induction, subcutaneous maintenance only, and an end of study at week 33. The ClinicalTrials.gov record was first posted on 2026-09-24, after enrollment was complete and 2 days after the top-line release, and it lists an estimated enrollment of 270 for both parts. Results are available only in a press release, investor presentations, and a call transcript, with no peer-reviewed publication and no results posted to the registry, and no health-related quality of life outcomes were reported.

VK2735-102 part 2 oral and subcutaneous maintenance

Objective
Location and study date
Study dates and United States sites in the ClinicalTrials.gov record (both study parts)
FieldRegistry value
Recruitment status“Recruiting”
Primary completion (estimated)“2027-05”
Study completion (estimated)“2027-07”
Site 1 city“Lake Forest”
Site 2 city“Miami”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary: study limitations

Part 2 of the VK2735-102 study began in October 2026, and no results have been reported; the company expects results in 2027. It is a phase 1 trial in approximately 195 otherwise healthy adults with a body mass index of at least 30 kg/m2, with a 12-week maintenance period after 21 weeks of weekly subcutaneous induction, a primary endpoint of treatment-emergent adverse events, and body weight change as an exploratory endpoint. The documents disagree on the regimens. The initiation release of 6 October 2026 listed “weekly oral doses”, and a correction note issued on 14 October 2026 removed them; the ClinicalTrials.gov record still lists a group receiving VK2735 “orally weekly” and a group receiving placebo “orally once weekly”. The registry describes 6 Part B arms receiving “one of four VK2735 dose regimens or matching placebo regimen”, while the chief executive officer described five oral arms and six subcutaneous arms. The oral doses have not been disclosed; the September 2026 call named 17.5, 27.5, and 55 mg, and the October 2026 call gave a range of about 17 to 55 mg. The registry estimate of 270 participants for both parts is smaller than the sum of the 180 participants randomized in Part 1 and the approximately 195 planned for Part 2.

VK2735-101 subcutaneous parts A and B

Objective
Location and study date
Single centre in Adelaide, Australia, in the ISRCTN record
FieldRegistry value
Countries of recruitment“Australia”
Study participating centre“Cmax Clinical Research Pty Ltd”
Date of first enrolment“01/12/2021”
Date of final enrolment“01/06/2023”
Planned study period“December 2021 to December 2022”
Study dates and site in the ClinicalTrials.gov record (Parts A, B, and C)
FieldRegistry value
Study start (actual)“2021-12-14”
Primary completion (actual)“2024-11-04”
Study completion (actual)“2024-12-03”
Site“Viking Clinical Site”
Site city“Adelaide”
Study design
Eligibility criteria
Treatment
Subcutaneous formulation: weekly dose levels in the multiple ascending dose cohorts
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record (Parts A, B, and C)
FieldRegistry value
Enrollment (actual)“92”
Participants analyzed in the multiple ascending dose cohorts
GroupParticipants analyzed for body weight
Placebo“(n=10)”
VK2735 0.5 mg“(n=6)”
VK2735 1.5 mg“(n=6)”
VK2735 1.5/3/5/5 mg“(n=7)”
VK2735 3/5/5/7.5 mg“(n=6)”
VK2735 5/5/7.5/10 mg“(n=6)”
Participants analyzed for liver fat
GroupParticipants analyzedSubset with nonalcoholic fatty liver disease
Placebo“(n=8)”“n=3”
VK2735 0.5 mg“(n=6)”“n=0”
VK2735 1.5 mg“(n=6)”“n=4”
VK2735 1.5/3/5/5 mg“(n=6)”“n=4”
VK2735 3/5/5/7.5 mg“(n=6)”“n=4”
VK2735 5/5/7.5/10 mg“(n=4)”“n=1”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Mean baseline body weight in the multiple ascending dose cohorts
GroupMean baseline body weight (kg)
Placebo (n=10)“121.1”
VK2735 0.5 mg (n=6)“101.2”
VK2735 1.5 mg (n=6)“114.8”
VK2735 1.5/3/5/5 mg (n=7)“115.3”
VK2735 3/5/5/7.5 mg (n=6)“116.3”
VK2735 5/5/7.5/10 mg (n=6)“95.9”
Mean baseline liver fat content in the multiple ascending dose cohorts
GroupMean baseline liver fat content (%)
Placebo (n=8)“6.59”
VK2735 0.5 mg (n=6)“2.58”
VK2735 1.5 mg (n=6)“7.84”
VK2735 1.5/3/5/5 mg (n=6)“8.14”
VK2735 3/5/5/7.5 mg (n=6)“11.1”
VK2735 5/5/7.5/10 mg (n=4)“3.96”
Efficacy results
Change in body weight by multiple ascending dose cohort at day 28
MeasurePlacebo (n=10)0.5 mg (n=6)1.5 mg (n=6)1.5/3/5/5 mg (n=7)3/5/5/7.5 mg (n=6)5/5/7.5/10 mg (n=6)
Mean change from baseline body weight“-2.2 kg”“-2.6 kg”“-4.1 kg”“-4.5 kg”“-8.2 kg”“-7.6 kg”
Mean percent change from baseline“-1.8 %”“-2.5 %”“-3.7 %”“-4.1 %”“-7.4 %”“-7.8 %”
Placebo-adjusted mean change from baseline“-”“-0.7 %”“-1.9 %”“-2.3 %”“-5.6 %”“-6.0 %”
p-value vs. placebo“-”“0.64”“0.17”“0.09”“0.0003”“0.0002”
Change in liver fat content by multiple ascending dose cohort
MeasurePlacebo0.5 mg1.5 mg1.5/3/5/5 mg3/5/5/7.5 mg5/5/7.5/10 mg
Mean percent change from baseline, all participants“-0.7”“3.9”“-24.2”“-24.0”“-47.2”“-8.4”
p-value vs. placebo, all participants“-”“0.74”“0.09”“0.10”“0.002”“0.62”
Mean percent change from baseline, nonalcoholic fatty liver disease subset“8.8”“-”“-33.8”“-32.5”“-49.7”“-10.7”
p-value vs. placebo, nonalcoholic fatty liver disease subset“-”“-”“0.03”“0.03”“0.006”“-”
Change in plasma lipids by multiple ascending dose cohort
MeasurePlacebo (n=9)0.5 mg (n=6)1.5 mg (n=6)1.5/3/5/5 mg (n=6)3/5/5/7.5 mg (n=6)5/5/7.5/10 mg (n=4)
Mean change in apolipoprotein B from baseline (%)“1.8”“3.3”“-1.8”“-12.9”“-12.5*”“-20.5”
Mean change in LDL-C from baseline (%)“-9.5”“1.4”“-10.6”“-13.7”“-20.3*”“-23.0”
Mean change in total cholesterol from baseline (%)“-5.1”“-1.7”“-10.8”“-14.9*”“-17.4*”“-21.0”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Commonly reported adverse events by multiple ascending dose cohort
Study limitations
Summary: study limitations

VK2735-101 Parts A and B were the first administration of VK2735 to humans, conducted at a single centre in Adelaide, Australia, in healthy adults (Part A) and otherwise healthy adults with a body mass index of at least 30 kg/m2 (Part B). The registered primary endpoint was the incidence of treatment-emergent adverse events, and body weight, liver fat, and lipids were exploratory pharmacodynamic measures. The multiple ascending dose part dosed participants once weekly for 4 weeks, with 6 or 7 participants in each VK2735 cohort and 10 receiving placebo, and the highest weekly dose (10 mg) is lower than the doses later carried into phase 2 and phase 3. The liver fat subgroup with nonalcoholic fatty liver disease contained 0 to 4 participants per cohort. Single-dose results by dose level, participant disposition, and baseline characteristics other than body weight and liver fat were not reported. The ISRCTN record named nonalcoholic steatohepatitis as the condition VK2735 was being developed for and a target sample size of 88; the ClinicalTrials.gov record reports an actual enrollment of 92 for Parts A, B, and C combined, whereas the oral first-in-human poster reports that 92 participants were randomized in the oral part alone. The two documents also differ on the time to maximum concentration (approximately 75 to 90 hours in the results release and about 72 hours in the corporate presentation). Results are available only in press releases, a corporate presentation, and a congress abstract, with no peer-reviewed full publication and no results posted to either registry.

VK2735-101 oral part C

Objective
Location and study date
Study dates and site in the ClinicalTrials.gov record (Parts A, B, and C)
FieldRegistry value
Primary completion (actual)“2024-11-04”
Study completion (actual)“2024-12-03”
Site city“Adelaide”
Study design
Eligibility criteria
Age range in the ClinicalTrials.gov record (Parts A, B, and C)
FieldRegistry value
Minimum age“18 Years”
Maximum age“65 Years”
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Oral formulation: participants analyzed by cohort
GroupEfficacy populationSafety population
Placebo“(n=18)”“(n=19)”
VK2735 2.5 mg“(n=8)”“(n=8)”
VK2735 5 mg“(n=6)”“(n=7)”
VK2735 10 mg“(n=6)”“(n=6)”
VK2735 20 mg“(n=8)”“(n=8)”
VK2735 40 mg“(n=7)”“(n=8)”
VK2735 60 mg“(n=9)”“(n=9)”
VK2735 80 mg“(n=9)”“(n=9)”
VK2735 100 mg“(n=9)”“(n=9)”
Actual enrollment in the ClinicalTrials.gov record (Parts A, B, and C)
FieldRegistry value
Enrollment (actual)“92”
Description of analysis sets
Results
Participant disposition
Oral formulation: early study discontinuation by cohort
GroupDiscontinued study early
Placebo (n=19)“2 (11%)”
VK2735 2.5 mg (n=8)“0 (0%)”
VK2735 5 mg (n=7)“1 (14%)”
VK2735 10 mg (n=6)“0 (0%)”
VK2735 20 mg (n=8)“0 (0%)”
VK2735 40 mg (n=8)“1 (13%)”
VK2735 60 mg (n=9)“1 (11%)”
VK2735 80 mg A (n=9)“1 (11%)”
VK2735 80 mg B (n=9)“0 (0%)”
VK2735 100 mg (n=9)“0 (0%)”
Baseline characteristics
Oral formulation: mean baseline characteristics by cohort
GroupAgeSex, M:F (%)White (%)Weight (kg)BMI (kg/m2)
Placebo (n=19)“38”“47:53”“68”“99”“36”
VK2735 2.5 mg (n=8)“34”“63:37”“75”“102”“36”
VK2735 5 mg (n=7)“29”“43:57”“71”“97”“34”
VK2735 10 mg (n=6)“35”“17:83”“100”“97”“36”
VK2735 20 mg (n=8)“35”“63:37”“88”“111”“36”
VK2735 40 mg (n=8)“33”“25:75”“63”“89”“33”
VK2735 60 mg (n=9)“44”“33:67”“89”“108”“37”
VK2735 80 mg (n=9)“44”“56:44”“100”“102”“35”
VK2735 100 mg (n=9)“44”“44:56”“67”“103”“35”
Efficacy results
Oral formulation: change in body weight by cohort at day 28
MeasurePlacebo (n=18)2.5 mg (n=8)5 mg (n=6)10 mg (n=6)20 mg (n=8)40 mg (n=7)60 mg (n=9)80 mg (n=9)100 mg (n=9)
Mean baseline body weight“98.3 kg”“102.3 kg”“95.3 kg”“97.1 kg”“111.3 kg”“90.0 kg”“107.7 kg”“102.0 kg”“102.7 kg”
Mean change from baseline body weight“-1.4 kg”“-0.3 kg”“-0.8 kg”“-1.3 kg”“-3.6 kg”“-4.8 kg”“-4.4 kg”“-5.3 kg”“-8.2 kg”
Mean percent change from baseline“-1.4 %”“-0.3 %”“-0.8 %”“-1.1 %”“-3.5 %”“-5.1 %”“-4.1 %”“-5.2 %”“-8.2 %”
Placebo-adjusted mean percent change from baseline“-”“1.0 %”“0.6 %”“0.3 %”“-2.2 %”“-3.7 %”“-2.7 %”“-3.9 %”“-6.8 %”
p-value vs. placebo“-”“-”“-”“-”“0.0174”“0.0001”“0.0026”“<0.0001”“<0.0001”
Percent reporting at least 5% weight loss“0 %”“0 %”“0 %”“0 %”“25 %”“57 %”“38 %”“63 %”“100 %”
p-value vs. placebo for at least 5% weight loss“-”“-”“-”“-”“0.0933”“0.0033”“0.0243”“0.0011”“<0.0001”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Oral formulation: adverse event summary by cohort
EventPlacebo (n=19)2.5 mg (n=8)5 mg (n=7)10 mg (n=6)20 mg (n=8)40 mg (n=8)60 mg (n=9)80 mg A (n=9)80 mg B (n=9)100 mg (n=9)
Treatment-emergent adverse events“16 (84%)”“6 (75%)”“6 (86%)”“4 (67%)”“6 (75%)”“7 (88%)”“9 (100%)”“9 (100%)”“8 (89%)”“9 (100%)”
Drug-related treatment-emergent adverse events“11 (58%)”“4 (50%)”“4 (57%)”“3 (50%)”“4 (50%)”“7 (88%)”“6 (67%)”“9 (100%)”“7 (78%)”“9 (100%)”
Serious adverse events“0 (0%)”“0 (0%)”“0 (0%)”“0 (0%)”“0 (0%)”“0 (0%)”“1 (11%)”“0 (0%)”“0 (0%)”“0 (0%)”
Study limitations
Summary: study limitations

VK2735-101 Part C was the first administration of the oral tablet formulation, in otherwise healthy adults with a body mass index of at least 30 kg/m2 who took VK2735 once daily for 28 days with follow-up to day 57. Safety and tolerability were the primary objectives, and body weight was an exploratory measure. Each VK2735 cohort had 6 to 9 participants and the pooled placebo group had 17 to 19, depending on the analysis; the every-other-day cohort at 80 mg had 9 participants. The tablet doses studied (2.5 to 100 mg) differ from the doses carried into phase 3 (27.5, 35, and 55 mg), and 28 days of dosing does not show where weight loss plateaus. Part C has no registry record of its own: the ClinicalTrials.gov record for NCT05203237 describes Part C in its detailed description but registers a single primary outcome, safety after single subcutaneous doses over 8 days, and reports an actual enrollment of 92 for Parts A, B, and C, the same number the poster reports as randomized in Part C alone. The interim release of March 2024 stated that “no serious adverse events (SAEs) have been reported to date” for cohorts through 40 mg; the poster reports one serious adverse event in the 60 mg cohort (1 of 9, 11%) without describing it. Results are available only in press releases, a corporate presentation, and a congress poster, with no peer-reviewed publication and no results posted to the registry.